Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in ...

Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune ...

BMS said it had invested in Israel-based Compugen and begun a clinical trial collaboration testing the latter’s COM7012, an investigational anti-PVRIG antibody in combination with Opdivo ...